Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646123 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT03646123: Clinical Trial Phase 2 study, sponsored by Seagen.
NCT03646123 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 255 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03646123, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C). The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening. Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.
Primary Outcome
The FN rate is defined as the number of participants who experience treatment-emergent FN.
Interventions
- DRUG G-CSF
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG vinblastine
- DRUG dacarbazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2024-08-23 |
| Phase | Phase 2 |
Why NCT03646123 stopped before completion
NCT03646123 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 5 interventions - of which G-CSF is the first listed.
NCT03646123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03646123 about?
NCT03646123 is a clinical study titled "Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma". This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have ...
What is the current status of trial NCT03646123?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2019-01-28. Estimated completion is 2024-08-23.
What interventions are being tested in trial NCT03646123?
The interventions under investigation include: G-CSF (DRUG), doxorubicin (DRUG), brentuximab vedotin (DRUG), vinblastine (DRUG), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT03646123?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03646123's enrollment target sits among peer trials
255 218th of 2000 higher than 1,782 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI